US Life Sciences Surge with AI-Driven Diagnostics and Pharma Deals in 2026
β’ The US life sciences industry gained momentum in 2026 despite NIH cuts and trade threats, fueled by AI advancements and major pharma deals. β’ Karius's AI genomic tests for immunocompromised patients detect 50% more pathogens in one day, analyzing millions of DNA reads after testing over 100,000 cases. β’ Biotech winter ended, shifting focus to preventive health via AI, data, and precise therapeutics amid administration priorities.
txbiomed.org












